Amunix and PolyPeptide Enter Into Partnership to Produce XTEN(TM) Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics
Picture Gallery, Venture Capital Tuesday, October 28th, 2014
MOUNTAIN VIEW, CA — (Marketwired) — 10/28/14 — Amunix Operating Inc., and PolyPeptide Laboratories, Inc. (PPL) have entered into a partnership under which Amunix–s proprietary recombinantly derived polypeptides (XTEN) will be chemically conjugated to other peptides. Under the terms of the Agreement, PPL will produce XTENylated peptides for third-party entities to facilitate evaluation of the resulting conjugates as therapeutic compounds. XTEN is Amunix–s proprietary protein-based polymer t
